Details for New Drug Application (NDA): 077833
✉ Email this page to a colleague
NDA 077833 describes NADOLOL AND BENDROFLUMETHIAZIDE, which is a drug marketed by Impax Labs and Natco Pharma and is included in two NDAs. Additional details are available on the NADOLOL AND BENDROFLUMETHIAZIDE profile page.
The generic ingredient in NADOLOL AND BENDROFLUMETHIAZIDE is bendroflumethiazide; nadolol. There are four drug master file entries for this compound. Additional details are available on the bendroflumethiazide; nadolol profile page.
The generic ingredient in NADOLOL AND BENDROFLUMETHIAZIDE is bendroflumethiazide; nadolol. There are four drug master file entries for this compound. Additional details are available on the bendroflumethiazide; nadolol profile page.
Summary for 077833
| Tradename: | NADOLOL AND BENDROFLUMETHIAZIDE |
| Applicant: | Impax Labs |
| Ingredient: | bendroflumethiazide; nadolol |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG;40MG | ||||
| Approval Date: | Mar 30, 2007 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG;80MG | ||||
| Approval Date: | Mar 30, 2007 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
